Free Trial

MLV & Co.'s Rating of BioCryst Pharmaceuticals on 12/22/2014

On December 22, 2014, MLV & Co. updated its outlook on BioCryst Pharmaceuticals (NASDAQ:BCRX) with the action "Set Price Target", setting a price target of $15.00. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.